V
4.74
-0.25 (-5.01%)
| 前收盘价格 | 4.99 |
| 收盘价格 | 5.00 |
| 成交量 | 557,376 |
| 平均成交量 (3个月) | 455,825 |
| 市值 | 279,349,504 |
| 预期市盈率 (P/E Forward) | 30.30 |
| 价格/销量 (P/S) | 1.37 |
| 股市价格/股市净资产 (P/B) | 0.550 |
| 52周波幅 | |
| 利润日期 | 30 Jul 2025 |
| 营业毛利率 | -21.98% |
| 营业利益率 (TTM) | -81.99% |
| 稀释每股收益 (EPS TTM) | -0.760 |
| 季度收入增长率 (YOY) | 5.40% |
| 总债务/股东权益 (D/E MRQ) | 2.30% |
| 流动比率 (MRQ) | 3.92 |
| 营业现金流 (OCF TTM) | -56.47 M |
| 杠杆自由现金流 (LFCF TTM) | -41.71 M |
| 资产报酬率 (ROA TTM) | -7.05% |
| 股东权益报酬率 (ROE TTM) | -8.39% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看跌 |
| Biotechnology (全球的) | 混合的 | 看跌 | |
| 股票 | Vanda Pharmaceuticals Inc. | 看跌 | 看涨 |
AIStockmoo 评分
0.4
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | -1.5 |
| 技术振荡指标 | 2.0 |
| 平均 | 0.38 |
|
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 7.16% |
| 机构持股比例 | 77.20% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Krensavage Asset Management, Llc | 31 Mar 2025 | 754,381 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 20.00 (HC Wainwright & Co., 321.94%) | 购买 |
| 中 | 16.50 (248.10%) | |
| 低 | 13.00 (Cantor Fitzgerald, 174.26%) | 购买 |
| 平均值 | 16.50 (248.10%) | |
| 总计 | 2 购买 | |
| 平均价格@调整类型 | 4.15 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Cantor Fitzgerald | 14 May 2025 | 13.00 (174.26%) | 购买 | 3.92 |
| HC Wainwright & Co. | 07 May 2025 | 20.00 (321.94%) | 购买 | 4.38 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合